Shasqi
Shasqi is a biotech company focused on making cancer drugs more effective through innovative click chemistry technology. Their proprietary CAPAC platform enables targeted activation of therapeutics at tumor sites, reducing systemic toxicity and expanding treatment possibilities. They are advancing a diverse pipeline of tumor-targeting agents and payloads, validated in clinical studies, with a mission to improve cancer treatment outcomes.
Industries
Nr. of Employees
small (1-50)
Products
Intratumoral biopolymer activator paired with systemically administered protodrugs
A therapeutic approach combining a locally delivered biopolymer activator that presents click-reactive groups at the tumor and a systemically dosed chemically attenuated protodrug that is activated on-site via in vivo click chemistry.
Systemically delivered protodrug payloads for multiple modalities
Protodrug constructs designed for chemotherapeutics, highly toxic cytotoxins, immune agonists and radiotherapeutic payloads that remain inactive in circulation until clicked at the tumor-localized activator.
CAPAC
Click Activated Protodrugs Against Cancer (CAPAC) is a pre-targeting platform that uses click chemistry to reunite a binder and payload at the tumor, avoiding off-target toxicities.
SQ3370
A clinical asset within the CAPAC platform that activates a doxorubicin protodrug at the tumor with an intratumorally injected biopolymer.
Intratumoral biopolymer activator paired with systemically administered protodrugs
A therapeutic approach combining a locally delivered biopolymer activator that presents click-reactive groups at the tumor and a systemically dosed chemically attenuated protodrug that is activated on-site via in vivo click chemistry.
Systemically delivered protodrug payloads for multiple modalities
Protodrug constructs designed for chemotherapeutics, highly toxic cytotoxins, immune agonists and radiotherapeutic payloads that remain inactive in circulation until clicked at the tumor-localized activator.
CAPAC
Click Activated Protodrugs Against Cancer (CAPAC) is a pre-targeting platform that uses click chemistry to reunite a binder and payload at the tumor, avoiding off-target toxicities.
SQ3370
A clinical asset within the CAPAC platform that activates a doxorubicin protodrug at the tumor with an intratumorally injected biopolymer.
Services
Collaborative research and development partnerships to apply in vivo click chemistry pre-targeting to external antigen targets and payloads, including co-development of activators and protodrugs.
Preclinical program execution including protodrug synthesis, activator design, animal efficacy and tolerability studies, PK/BD analysis, and immune response assessment to support clinical translation.
Collaborative research and development partnerships to apply in vivo click chemistry pre-targeting to external antigen targets and payloads, including co-development of activators and protodrugs.
Preclinical program execution including protodrug synthesis, activator design, animal efficacy and tolerability studies, PK/BD analysis, and immune response assessment to support clinical translation.
Expertise Areas
- Pre-targeting oncology therapeutics
- In vivo bioorthogonal (click) chemistry
- Protodrug (prodrug) design and medicinal chemistry
- Tumor-targeting activator engineering (antibodies, fragments, peptides, VHH)
Key Technologies
- In vivo click chemistry (bioorthogonal reactions)
- Chemical protodrug design and attenuation
- Injectable biopolymer activators (hyaluronate derivatives)
- Antibody- and peptide-based targeting agents
News & Updates
Shasqi published a landmark study in Clinical Cancer Research detailing the development and first-in-human trial of SQ3370, a click chemistry-based cancer therapeutic that allows higher doses of doxorubicin to be delivered directly to tumors with reduced toxicity.
A significant publication by Shasqi in Clinical Cancer Research highlights the first-in-human use of click chemistry for targeted cancer therapy, demonstrating the platform's potential to revolutionize oncology treatments.
Shasqi published a landmark study in Clinical Cancer Research detailing the development and first-in-human trial of SQ3370, a click chemistry-based cancer therapeutic that allows higher doses of doxorubicin to be delivered directly to tumors with reduced toxicity.
A significant publication by Shasqi in Clinical Cancer Research highlights the first-in-human use of click chemistry for targeted cancer therapy, demonstrating the platform's potential to revolutionize oncology treatments.